UOC
XLRN

UBS O'Connor’s Acceleron Pharma XLRN Stock Holding History

UBS O'Connor’s Portfolio XLRN Stock Details XLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-49,100
Closed -$1.3M – 545
2016
Q1 		$1.3M Buy
+49,100
New +$1.43M 0.01% 348

Other funds holding XLRN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PVMCI
Polaris Venture Management Co IV Boston, Massachusetts $62.4M AUM 33.04% 1-Year Est. Return
ORI
Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.81B AUM 83.9% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

UBS O'Connor's XLRN Position: Q2 2016 in Review

UBS O'Connor sold out of Acceleron Pharma (XLRN) in Q2 2016, closing a stake of 49,100 shares — an estimated $1.3M sold.

UBS O'Connor first reported a position in XLRN in Q1 2016 and held it in 1 quarter. The position peaked at $1.3M in Q1 2016. 136 funds tracked by Wall St. Rank hold XLRN as of Q2 2016.

  • UBS O'Connor reported no remaining Acceleron Pharma position as of Q2 2016 after selling out during the quarter.
  • UBS O'Connor sold 49,100 Acceleron Pharma shares in Q2 2016, an estimated $1.3M.
  • UBS O'Connor first reported a position in Acceleron Pharma in Q1 2016 and held it in 1 quarter.
  • UBS O'Connor's Acceleron Pharma position peaked at $1.3M in Q1 2016.
  • 136 funds tracked by Wall St. Rank held Acceleron Pharma as of Q2 2016.

Based on UBS O'Connor's 13F filing for Q2 2016, filed 12 Aug 2016.